Banoxantrone

Drug Profile

Banoxantrone

Alternative Names: AQ4N; AZD 1689

Latest Information Update: 02 Feb 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of London School of Pharmacy
  • Developer Novacea; Transcept Pharmaceuticals Inc
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; B cell lymphoma; Glioblastoma

Most Recent Events

  • 02 Feb 2009 Novacea has merged with Transcept Pharmaceuticals to form Transcept Pharmaceuticals Inc
  • 15 Feb 2008 Pharmacokinetics data from a phase I proof-of-principle trial in solid tumours released by Novacea
  • 03 Jan 2008 Novacea has scaled back development of banoxantrone, discontinuing the phase II trial in acute lymphoblastic leukaemia and delaying the planned clinical trial in B cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top